Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

Published:2021-12-31 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Jong Evelien J. M.¹^ORCID,Janssen Quisette P.²,Simons Tessa F. A.¹,Besselink Marc G.³,Bonsing Bert A.⁴,Bouwense Stefan A. W.⁵,Geurts Sandra M. E.¹,Homs Marjolein Y. V.⁶,Meijer Vincent E.⁷,Tjan‐Heijnen Vivianne C. G.¹,Laarhoven Hanneke W. M.⁸,Valkenburg‐van Iersel Liselot B. J.¹,Wilmink Johanna W.⁸,Geest Lydia G.⁹,Koerkamp Bas Groot²,Vos‐Geelen Judith¹^ORCID,

Affiliation:

1. Department of Internal Medicine, Division of Medical Oncology, GROW ‐ School for Oncology and Developmental Biology Maastricht University Medical Center+ Maastricht The Netherlands

2. Department of Surgery Erasmus MC Cancer Institute Rotterdam The Netherlands

3. Department of Surgery, Amsterdam UMC University of Amsterdam, Cancer Center Amsterdam Amsterdam The Netherlands

4. Department of Surgery Leiden University Medical Center Leiden The Netherlands

5. Department of Surgery Maastricht University Medical Center+ Maastricht The Netherlands

6. Department of Medical Oncology Erasmus Medical Center Rotterdam The Netherlands

7. Department of Surgery University of Groningen and University Medical Center Groningen Groningen The Netherlands

8. Department of Medical Oncology, Amsterdam UMC, University of Amsterdam Cancer Center Amsterdam Amsterdam The Netherlands

9. Department of Research Netherlands Comprehensive Cancer Organization (IKNL) Utrecht The Netherlands

Funder

KWF Kankerbestrijding

ZonMw

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33916

Reference33 articles.

1. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

2. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

3. Cancer statistics, 2018

4. Pancreatic Adenocarcinoma

5. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study;Frontiers in Oncology;2023-10-16

2. Reply to C. Springfeld et al;Journal of Clinical Oncology;2023-09-01

3. Chain length impact on the retro Diels-Alder mediated release of gemcitabine from hybrid nanoparticles towards pancreatic cancer therapy;International Journal of Pharmaceutics;2023-09

4. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohort study;International Journal of Surgery;2023-08-11

5. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective;Cancer Control;2023-04